Professor Chen Wang, Director of the Centre for Respiratory Medicine at Beijing\'s China--Japan Friendship Hospital, is the new President of the Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC). Of the several reasons for welcoming the appointment, the most obvious is Wang\'s expertise in the respiratory diseases that are a leading cause of morbidity and mortality in his country and impose a great socioeconomic burden. Moreover, he makes no secret of his enthusiasm for curbing tobacco use, which, while now recognised by the Chinese Government as a key public health issue, remains high. And although a thorough-going academic researcher, he\'s also eager to see the fruits of his and others\' research translated into clinical practice.

A physician who knows Wang is Bruce Davidson, sometime clinical professor in the Pulmonary-Critical Care Medicine Division at the University of Washington School of Medicine in Seattle. Davidson is also an associate editor of the journal *CHEST*, which is how he first came across Wang. "The editor-in-chief asked me to review a paper by Chen Wang and a consortium of doctors in which for the first time they gave a reduced dose of a thrombolytic drug to people with embolisms. This was a brave thing to do in people who were critically ill." There were no previous studies, so Wang and his colleagues were breaking new ground. "In 2010, when it \[the paper\] finally appeared, it changed practice", he says.

Wang studied medicine at the Capital Medical University in Beijing. But the thought of becoming a doctor had been in his mind long before he enrolled as a student. "My parents were university professors, but not doctors", he says. "They were in the humanities. Before I chose my career they suggested I might become a doctor because it\'s an honourable career and you do work that benefits other people." Wang didn\'t take much persuading; he liked the hospital environment, and had done so since going to hospital as a child. In the choice of respiratory medicine as a speciality, he was influenced by his mentor Weng Xinzhi, a former Director of the Beijing Institute of Respiratory Medicine and sometimes described as the father of tobacco control in China.

Following his graduation in 1985, Wang spent the next 25 years at Beijing\'s Chao-Yang Hospital, joining it as a resident physician and leaving it as hospital president. After 3 years at Beijing Hospital and a further year at the Ministry of Health, he returned to clinical medicine and research as President of the China--Japan Friendship Hospital. Then came the CAMS and PUMC appointment: one which Davidson applauds. He first met Wang in person during the visit of a US medical delegation to China, and their shared interest led them to work together. "My collaboration with him has been in conceiving and executing studies on the prevention and treatment of pulmonary embolism", says Davidson, adding that Wang has a good brain for moving the best of science into practical use.

Underpinning Wang\'s presidential, administrative, teaching, and policy work ("I have 4 hours to sleep at night," he jokes) are his research achievements. Besides the ground-breaking thrombolysis findings, he headed a national epidemiological study of chronic obstructive pulmonary disease---it turned out to be more than twice as common as previously believed---and led the world\'s largest clinical trial of extracorporeal membrane oxygenation (ECMO) for managing respiratory failure. The latter formed the foundations on which he then proceeded to draft the first international guidelines for implementing ECMO. As a leading respiratory physician, he had a prominent role in tackling the 2003 outbreak of severe acute respiratory syndrome and the 2009 H1N1 influenza epidemic. He\'s also overseen an expert panel set up to develop new strategies for controlling infections of these kinds.

All in all a rich and varied record of achievement. Also of importance, in the view of epidemiologist Professor Zhengming Chen, is Wang\'s concern with smoking. Chen is Director of China Programmes in the Nuffield Department of Population Health at the UK\'s University of Oxford. "Wang is one of only a few individuals in China with a clinical background and a strong vision for public health...and big strategies at the population level." And that includes strategies for tackling tobacco. As Wang himself puts it: "Tobacco is the number one cause of respiratory disease in China. The rate of smoking in China is really high...It\'s the number one factor for disease control." Like Davidson, Chen is delighted by the choice of Wang as CAMS President. "There\'s a belief among some basic scientists that population science is not real science...it\'s not challenging enough." Wang\'s presidency will be good for the relevance of medical science to the needs of the Chinese people, Chen believes. He foresees more and wider interdisciplinary collaborations. "Wang is a good leader with a charming personality", according to Chen. "He\'s also interested in patients, not just in disease. He\'s easy-going, very humble." Davidson adds that Wang not only talks but listens. "He keeps his ego firmly in his back pocket."

As for the future, Wang sees CAMS serving as a unique platform to enhance national and international collaboration in medical innovations and advances. "I would hope to improve CAMS\'s pivotal role in leading and transforming medical research and education in China", he says, "as well as establishing a comprehensive medical research system to strengthen the capacity of Chinese researchers. This will ultimately benefit the health of our 1·4 billion Chinese population."
